|
06-28-10: [Lupron] used for endometriosis and prostate cancer linked to misery for patients (yet another attorney ad)
06-16-10: "Abbott will look to replace Lupron in the Ob/Gyn market with Elagolix" (lupron loses patent protection in 2015)
05-03-10: FDA conducting safety review of lupron in prostate cancer use
04-23-10: FDA sends Letter re: Eligard promotion
04-22-10: Lupron sales fell 10.4% to $172 million
Abbott 2009 Q4 Profits - Lupron sales down 3.6% @ $141 million
2-1-10: Two Mass. hospitals drop leuprolide depot - save $120,000 annually
11-06-09: Abbott faces new US sales probe, Depakote in Focus
10-29-09: "Even though criminal indictments were filed against TAP Pharmaceutical officials, Lupron’s price remains overly inflated."
05-21-09: Leftover $11.4 million from Lupron price inflation class action settlement may go to Harvard for prostate cancer research
Abbott CEO pay/package is rated #1 @ $33.4 million (see page 17)
Various New Lupron/leuprolide FDA Drug Approvals (search under 'L')
MSDS: leuprolide = "Hazardous per OSHA criteria"
Leuprolide price-gouging: 437 % mark-up
Abbott 2009 Second Quarter: Lupron Sales Increased 28.3%
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Millican's US Attorney Draft Document :
IIa: Was Lupron's Initial Male FDA Approval Based Upon 'Safety' and 'Efficacy'?
IIb: Was Lupron's Initial Female FDA Approval Based Upon 'Safety' and 'Efficacy'?
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
06-24-02: A Whistle-Blower Rocks an Industry
2007: leuprolide 45 mg - FDA Notice of Initiation of Disqualification Proceedings
2005: Recall - 16,275 Lupron 7.5 & 30 mg for "clumping"
2003: Lupron diverted
Information on FDA's 1999 review of lupron, as found within Boston Herald's 8-22-99 article (beginning on pg. 2 of this link)
2001 - U.S. Dept of Justice: "TAP settles charges"
2001: TAP/Abbott sued for racketeering (Russano v. TAP/Abbott, filed 9-7-01, Federal Court, Chicago)
1-24-03: Memorandum & order on Takeda's motion to dismiss in Re: Lupron Marketing & Sales Practices Litigation (Russano & Goetting DENIED)
Substantial review of Lupron's litigation history re: racketeering can be found here (beginning on page 3)
2000 - Questions posed to TAP and FDA by the now-defunct NLVN about lupron
2000 - A review by the now-defunct NLVN on the FDA's role in lupron
FDA's 5-29-97 Warning Letter to TAP re: misleading claims in prostatic use
FDA's 3-9-90 letter to TAP re: misleading urology claims
FDA's '90 Notice of Adverse Findings vs. Lupron/TAP
FDA's 3-90 memo re: TAP's indocrination of MD's to lupron's off-label uses
Incomplete A-Z list of lurpon / leuprolide 'Off-Label Uses'
TAP's connection with autism patent by Kathleen Seidel
8-90 letter from TAP to Millican promoting off-label Lupron (b4 endo approval)
TAP's '90 Response to FDA
2001: Abbott/TAP designated as one of worst corporation
Lupron'$ 'Whi$tleblower'
Lupron: "Marketing The Spread" (scroll down)
1998: 53% of urologists surveyed "did not believe in efficacy" of ADT but they still prescribed it
Abbott / Takeda pay $875 million to settle Lupron Fraud Case
Review of billing fraud details
Post on CafePharma 12-22-05 (07:35 pm): "Re: Challenge: All Lupron 'Haters' Invited" - "GYNs slid under radar ..."
Medicare Reimbursement for Lupron
'98 Letter to Editor, Boston Herald, re: Lupron Fraud, Conflict$ of Interest
1992 Abbott Annual Report: Clinical studies "underway" for lupron's effectiveness in infertility (Note: Why no "safety" study, and Why hasn't lupron ever been FDA approved for infertility or IVF treatment?)
Collection of old news bits re: TAP, Abbott, lupron, etc. (i.e. Notices of Adverse Findings, FEC Warnings, Annual Report details, etc.)
Example of Using Leuprolide on Women BEFORE use of Leuprolide in Animals (note "Conclusion")
ALADDIN Study - Leuprolide & Alzheimers Trial
Example of promoting lupron for non-approved indications: "leuprolide is prescribed to shrink the fibroids"
Lupron & Fraudulent Research (Known Instances)
'96: Findings of Scientific Misconduct in TAP's lead lupron investigator
Published Lupron Article "Retracted" For Fraudulent Data (re: gyn)
Another Published Article re: Leuprolide "Retracted" Due to 'Undiscoverable Reasons' (re: autism)
|
This page will address some of the history of lupron, TAP (Takeda Abbott Phamaceuticals), and Abbott. After a 31 year joint venture, Takeda and Abbott dissolved their partnership in 5/08, and lupron is now under Abbott's purview.
Information related to FDA's initial approval of lupron in men and women can be found within my 'USA[ttorney] Draft Document', which contains substantive information on the following themes:
II. WAS LUPRON'S INITIAL [MALE & FEMALE] FDA APPROVAL BASED UPON SAFETY AND EFFICACY?
III. HAVE TAP, INVESTIGATORS, AND PHYSICIANS REPORTED ACCURATE AND FULL DATA REGARDING LUPRON?
IV. HAVE TAP, INVESTIGATORS, AND PHYSICIANS KNOWINGLY HARMED BABIES CONCEIVED WITH LUPRON?
V. HAVE STATE AND FEDERAL GOVERNMENT AGENCIES ACTED ON BEHALF OF CONSUMERS RELATIVE TO LUPRON?
VI. WHAT ROLE HAS CONFLICTS OF INTEREST PLAYED IN THE HUMAN EXPERIMENTATION, SUPPRESSION OF INFORMATION, AND LACK OF MEDICO-LEGAL ADVOCACY RELATIVE TO LUPRON?
VII. HAVE THERE ALSO BEEN GYNECOLOGICAL AND REPRODUCTIVE SCHEMES BY TAP, INVESTIGATORS AND PHSYCIANS?
-------------------
Other documents on this page pertain to TAP's propensity for off-label promotion of lupron, and TAP's ultimate guilty plea in Medicare billing fraud.
This page is under construction.
|
|
